Archives
Extremely rare cases of Guillain-Barré reported with Johnson & Johnson vaccine for Covid-19.
13 Jul, 2021 | 09:48h | UTCJ&J’s Covid-19 vaccine may trigger neurological condition in rare cases, FDA says – STAT
See also: Johnson & Johnson Vaccine Is Linked To Neurological Disorder In Extremely Rare Cases – NPR AND F.D.A. Attaches Warning of Rare Nerve Syndrome to Johnson & Johnson Vaccine – The New York Times
Pro-Con Debate | Should we delay covid-19 vaccination in children?
13 Jul, 2021 | 09:51h | UTCShould we delay covid-19 vaccination in children? – The BMJ
News release: Should we delay COVID-19 vaccination in children? – British Medical Journal
Commentary on Twitter
Covid-19 vaccines in adults have been remarkably effective. There is good reason to expect that the same will be true in children.
A group of authors discuss the pros and cons of vaccinating children against covid-19 https://t.co/TOEI67YPeH
— The BMJ (@bmj_latest) July 9, 2021
WHO issues new recommendations on human genome editing for the advancement of public health.
13 Jul, 2021 | 09:42h | UTCSee reports:
Human genome editing: recommendations
Human genome editing: a framework for governance
Commentaries: New Global Recommendations for Human Genome Editing may Improve Use to Cure and Treat Diseases – Health Policy Watch AND WHO should lead on genome-editing policy, advisers say – Nature AND WHO Calls for Global Registry of Human Genome Editing – HealthDay AND Expert reaction to the WHO’s newly published recommendations and governance framework for human genome editing – Science Media Centre
Commentary on Twitter (thread – click for more)
Two 🆕 reports provide the first global recommendations to help establish human genome 🧬 editing as a tool for public health, with an emphasis on safety, effectiveness and ethics.
👉 https://t.co/w32QhMXSXi pic.twitter.com/Bto9SF6NzW
— World Health Organization (WHO) (@WHO) July 12, 2021
Another RCT evaluating the efficacy and quality of life of antibiotic-only treatment of acute uncomplicated appendicitis.
13 Jul, 2021 | 09:33h | UTCA Randomized Clinical Trial Evaluating the Efficacy and Quality of Life of Antibiotic-only Treatment of Acute Uncomplicated Appendicitis: Results of the COMMA Trial – Annals of Surgery (link to abstract – $ for full-text)
Related: A Randomized trial comparing antibiotics with appendectomy for appendicitis AND Antibiotics alone for uncomplicated appendicitis: Oral Moxifloxacin almost as good as intravenous Ertapenem + oral Levofloxacin AND Observational study: 67.1% success rate with nonoperative management of children with uncomplicated appendicitis AND Randomized Trial: Quality of Life and Patient Satisfaction at 7-Year Follow-up of Antibiotic Therapy vs. Appendectomy for Uncomplicated Acute Appendicitis AND Meta-Analysis: Antibiotic Treatment vs. Appendectomy for Uncomplicated Acute Appendicitis in Adults and Children AND Nonoperative treatment for nonperforated appendicitis in children: a systematic review and meta-analysis – Pediatric Surgery International
Commentary on Twitter
The debate continues!
Another RCT comparing antibiotics to surgery for uncomplicated appendicitis – COMMA trial from 🇮🇪
Recurrence within 1-year : 25% after AB
Superior quality of life at 3 and 12mo after surgery.https://t.co/Yv51qpxchb
— Ville Sallinen (@villesallinen) July 11, 2021
2021 ACR Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.
13 Jul, 2021 | 09:41h | UTC
Podcast | An Antibiotics Primer.
13 Jul, 2021 | 09:35h | UTC#284 An Antibiotics Primer, with @IDdocAdi – The Curbsiders
WHO criticizes rich countries for planning COVID vaccine ‘boosters’ – while billions wait for first jab.
13 Jul, 2021 | 09:45h | UTCCOVID-19 booster strategy as Delta multiplies, highlights ‘disappointing inequality’: WHO – UN News
See also: WHO Lambasts Pfizer, Moderna & Rich Countries for Planning COVID Vaccine ‘Boosters’ – While Billions Wait for First Jab – Health Policy Watch AND WHO says vaccinated countries must stop ordering booster shots until others are fully vaccinated – ABC News
2021 ACR Guideline for the Management of Polyarteritis Nodosa.
13 Jul, 2021 | 09:37h | UTC
M-A: Similar mortality with Fluoroquinolones or Macrolides for the treatment of Legionella Pneumonia.
13 Jul, 2021 | 09:18h | UTCAre Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis – Clinical Infectious Diseases (link to abstract – $ for full-text)
Review: Infectious disease-associated encephalopathies.
13 Jul, 2021 | 09:30h | UTCInfectious disease-associated encephalopathies – Critical Care
Commentary on Twitter
A Review published in Critical Care focuses on the pathophysiology of encephalopathies associated with sepsis, malaria, influenza, and COVID-19; emerging therapeutic strategies; and the role of neuroinflammation. https://t.co/991S4kAKJk
— BMC (@BioMedCentral) July 11, 2021
Top 10 pearls for the recognition, evaluation, and management of maternal sepsis.
13 Jul, 2021 | 09:25h | UTC
M-A: Global prevalence of functional constipation according to the Rome criteria.
13 Jul, 2021 | 09:17h | UTC
Commentary on Twitter
New research – Barberio et al – Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysishttps://t.co/pqkXltWnYU#constipation #gitwitter @bribarberio @DrCJudge @EdoardoSavarino @alex_ford12399 pic.twitter.com/NUnZgaVS46
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) June 4, 2021
RCT: Comparison of nebulized ketamine at three different dosing regimens for treating painful conditions in the emergency department.
13 Jul, 2021 | 09:22h | UTCComparison of Nebulized Ketamine at Three Different Dosing Regimens for Treating Painful Conditions in the Emergency Department: A Prospective, Randomized, Double-Blind Clinical Trial – Annals of Emergency Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Nebulized Ketamine for pain in the ED? No way…Well- here you go-Comparison of Nebulized Ketamine at Three Different Dosing Regimens for Treating Painful Conditions in the ED. https://t.co/v3UT0Y0LdU #FOAMed #FOAMems #FOAMtox #FOAMcc #FOAMpharm
— Sergey Motov (@painfreeED) July 3, 2021
RCT: Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma.
13 Jul, 2021 | 09:20h | UTC
Commentary on Twitter
Long-term outcomes from the NEOCRTEC5010 demonstrated the survival benefit of neoadjuvant chemoradiotherapy followed by surgery compared with surgery alone for patients with locally advanced esophageal squamous cell carcinoma https://t.co/UBBEEAynsy
— JAMA Surgery (@JAMASurgery) June 29, 2021
[Preprint] Heparin for Moderately Ill Patients with Covid-19 – “In moderately ill ward patients with Covid-19 and elevated D-dimer level, therapeutic heparin did not significantly reduce the primary outcome but decreased the odds of death at 28 days”.
12 Jul, 2021 | 03:14h | UTCHeparin for Moderately Ill Patients with Covid-19 – medRxiv
Related: RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk. AND [Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups. AND [Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19
Commentary on Twitter (thread – click for more)
🚨Final results of the RAPID trial now pub'd @medrxivpreprint 🚨 RAPID was an open-label trial that randomly assigned hospitalized ward patients with COVID-19 and elevated D-dimer levels to therapeutic or prophylactic heparin. 🧵 1/10 https://t.co/oxiyXQAPeK pic.twitter.com/V2GtruEyM2
— Michelle Sholzberg (@sholzberg) July 9, 2021
New CDC Guidance for COVID-19 prevention in kindergarten schools says safely returning to in-person instruction is a priority.
12 Jul, 2021 | 03:11h | UTCCommentaries: Updated CDC schools guidance prioritizes in-person learning, even if all Covid-19 safety measures aren’t in place – CNN AND The C.D.C. Issues New School Guidance, With Emphasis on Full Reopening – The New York Times AND New CDC guidance says fully vaccinated teachers and students don’t need to wear masks indoors – CNBC AND CDC calls for reopening schools fully, recommends masking – CIDRAP
Related: COVID and schools: the evidence for reopening safely – Nature
[Preprint] Study confirms children’s extremely low risk of death from Covid-19 – “99·995% of children and young people with a positive SARS-CoV-2 test survived”.
12 Jul, 2021 | 03:12h | UTCCommentaries: Risks of severe illness in children from COVID-19 shown to be very low in largest study yet – University of Liverpool AND Covid: Children’s extremely low risk confirmed by study – BBC
Related study from the same group (preprint): Risk factors for intensive care admission and death amongst children and young people admitted to hospital with COVID-19 and PIMS-TS in England during the first pandemic year – medRxiv
RCT: Another study shows Azithromycin does not improve outcomes in patients with Covid-19.
12 Jul, 2021 | 03:09h | UTCCommentaries: Trial shows that the antibiotic azithromycin does not prevent mild COVID cases progressing to hospitalization, death – European Society of Clinical Microbiology and Infectious Diseases AND Azithromycin: can its benefit be ruled out in mild COVID-19? – The Lancet Respiratory Medicine
Related: M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19. AND RCT: Azithromycin provides no benefit for community treatment of patients with suspected COVID-19 AND RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19 AND [Press release – not published yet] Azithromycin and doxycycline are not generally effective against COVID-19 in patients treated at home, shows PRINCIPLE trial AND Coalition Covid-19 Brazil – Randomized trial: Azithromycin not beneficial for patients admitted to the hospital with severe Covid-19 AND Coalition Covid-19 Brazil – Randomized trial: hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19
Commentary on Twitter
In patients with mild-to-mod #COVID19 managed without hospital admission, azithromycin + SOC did not reduce the risk of subsequent hospital admission or death
Read the ATOMIC2 trial here https://t.co/QXJ7T08JZS, being presented at #ECCMID2021 by lead author Tim Hinks @HinksLab pic.twitter.com/ZDiPhuQqFB
— The Lancet Respiratory Medicine (@LancetRespirMed) July 9, 2021
Monitoring blood pressure at home: guidance for Canadian patients.
13 Jul, 2021 | 09:15h | UTC
A correlate of protection for SARS-CoV-2 vaccines is urgently needed – “Recent studies suggest that neutralizing antibodies could serve as a correlate of protection for vaccines against SARS-CoV-2 in humans”.
12 Jul, 2021 | 03:03h | UTCA correlate of protection for SARS-CoV-2 vaccines is urgently needed – Nature Medicine
Public Health England: COVID-19 vaccines highly effective in clinical risk groups.
12 Jul, 2021 | 03:06h | UTCCOVID-19 vaccines highly effective in clinical risk groups – Public Health England
Commentaries: Covid vaccines do work well in clinically vulnerable – BBC AND Public Health England says Pfizer, AstraZeneca vaccines effective in high-risk groups – Reuters
Commentary on Twitter (thread – click for more)
NEWS: #COVID19 #vaccines highly effective in clinical risk groupshttps://t.co/mkVnxTqOrJ pic.twitter.com/M6Me98SRln
— UK Health Security Agency (@UKHSA) July 9, 2021
Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.
12 Jul, 2021 | 03:08h | UTCPfizer says it’s time for a Covid booster; FDA and CDC say not so fast – CNN
See also: CDC, FDA contradict Pfizer on COVID-19 vaccine booster – CIDRAP AND Do I need a COVID-19 booster shot? 6 questions answered on how to stay protected – The Conversation AND Pfizer suggests booster shots will be needed this year, but government officials say science will dictate the timing – The Washington Post AND Pfizer to seek OK for 3rd vaccine dose; shots still protect – Associated Press AND Citing the Delta Variant, Pfizer Will Pursue Booster Shots and a New Vaccine – The New York Times (a few articles per month are free) AND Question open on need for COVID booster shot, data awaited, WHO says – Reuters
Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report.
12 Jul, 2021 | 01:41h | UTC
Can we stretch existing Covid vaccines to inoculate more people? Experts are divided.
12 Jul, 2021 | 03:05h | UTCCan we stretch existing Covid vaccines to inoculate more people? Experts are divided – STAT
See also: Quarter-dose of Moderna COVID vaccine still rouses a big immune response
Lambda, the Newest WHO Variant of Interest, is Now in 29 Countries.
12 Jul, 2021 | 03:06h | UTCLambda, the Newest WHO Variant of Interest, is Now in 29 Countries – Health Policy Watch